Journal of Clinical Oncology · 2005 · 94 citations · 38 references
MedicineOncologyPharmacotherapyImmunotherapyMolecular OncologyStem Cell TransplantationDose EscalationHematologic Malignancy TherapyHematopoietic Stem Cell Transplant PharmacotherapyMinimal Residual DiseaseAllogeneic Stem Cell TherapyBcr-abl InhibitorsBcr-abl1 Fusion GenePost-transplant Residual Disease MonitoringQuantitative Polymerase Chain ReactionQuantitative Polymerase Chain Reaction AssaysTreatment Algorithm DevelopmentTyrosine Kinase Inhibitor Therapy
PURPOSE: In the era of molecular therapy of chronic myelogenous leukemia (CML) applying BCR-ABL tyrosine kinase inhibitors, the usefulness of molecular end points, in particular, quantitative polymerase chain reaction (PCR) for BCR-ABL in monitoring responses has been broadly accepted. Therefore, we have designed a prospective phase II trial in CML, which, for the first time, evaluated the feasibility and safety of molecular end points as surrogate markers to guide through a stratified treatment algorithm within a multicenter trial. PATIENTS AND METHODS: As a clinical model, we adopted minimal residual disease (MRD) found in relapse after allogeneic stem cell transplantation (SCT) in CML. Forty-four patients were enrolled and received the BCR-ABL tyrosine kinase inhibitor imatinib (IM) at a starting dose of 400 mg/d. The quality of molecular responses achieved then decided on discontinuation of IM or dose escalation up to 800 mg/d, and finally, on application of donor lymphocyte infusions. Results Seventy percent of patients achieved a complete molecular response (CMR), defined as nested PCR-negativity for BCR-ABL in three consecutive samples. Interestingly, in four out of 10 patients who discontinued IM, CMR was durable even after cessation of IM with a median follow-up of 494 days. This suggests the possibility of long-term tumor control in a subset of patients. CONCLUSION: The treatment strategy showed that IM treatment was well-tolerated and highly efficacious in MRD after allogeneic SCT. Moreover, this study demonstrated that evaluation of a molecular end point within a multicenter trial can be a safe and effective tool for clinical decision making.
38
Graft-versus-leukemia reactions after bone marrow transplantation
MM Horowitz, Gale Rp, Sondel Pm et al. · Blood · 1990 · 2.8K citations · Full text
Medicine, Hematology, Immunology +11